Log inSign up
Andrea Necchi
2,938 posts
user avatar
Andrea Necchi
@AndreaNecchi
Associate Professor @MyUniSR - Director of Genitourinary Medical Oncology @SanRaffaeleMI - Vice President @GTumors - Associate Editor @JCO_ASCO
Milano
Joined April 2012
958
Following
4,397
Followers
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Feb 22, 2025
    A Clinical Gene Therapy Study with Hematopoietic Stem Cells for the Treatment, with Single Dose of Temferon, of Patients with Metastatic Renal Cell Carcinoma | ClinicalTrials.gov ⁦@GenentaScience⁩ ⁦@MyUniSR⁩ ⁦@SanRaffaeleMI⁩ clinicaltrials.gov/study/NCT06716…
    457K
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Mar 18, 2020
    The new ICU @SanRaffaeleMI realized in 2 weeks is almost ready for the fight against #coronavirus This is the 🇮🇹spirit, not the songs at the balcony
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Oct 3, 2022
    3-y FUP update of #PURE01. RFS/EFS confirm early positive data, w potential benefit across ypTN categories. @BasileG_ @BandiniMd @MyUniSR @SanRaffaeleMI aacrjournals.org/clincancerres/…
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    May 14, 2024
    Profoundly honored to serve as new Associate Editor ⁦@JCO_ASCO⁩ continuing the path of Mike Carducci | a special thank to the EiC ⁦@DrJFriedberg⁩ and the exceptional editorial staff ⁦@ASCO⁩ ⁦@MyUniSR⁩ ⁦⁦@SanRaffaeleMI⁩
    ascopubs.org
    Editorial Roster | Journal of Clinical Oncology
    16K
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Jun 7, 2023
    My take on #VESPER study: 🍸ddMVAC confirms to be a very cool regimen used in referral centers (including mine). Congrats to authors! 🫙N. cycles of chemo needed to cure pts remains unknown 🍼translation in real world remains challenging 🧃Validity of conclusion slide uncertain
    59K
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Oct 30, 2023
    Incredibly honored and humbled to receive today the “Beppe Della Porta” award by @AIRC_it from the hands of our President Sergio Mattarella @Quirinale in recognition of the huge work of my entire team @SanRaffaeleMI @MyUniSR @RaiUno @ElisirTv
    19K
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Mar 28, 2021
    I am pleased to share our last platinum priority paper from collaborative work: Molecular Characterization of Residual Bladder Cancer after Neoadj Pembrolizumab @ewanagibb @JoepJdeJong @pcvblack @Roland3097 @DanieleRaggi83 @LauraLmar89 #PURE01 @EUplatinum europeanurology.com/article/S0302-…
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Oct 14, 2020
    Meaningful new data published today in MIBC. It becomes clear that validating the role of pCR as surrogate biomarker of OS/EFS after checkpoint inhibition alone is primarily needed @sonpavde @drenriquegrande @ewanagibb @shilpaonc @urotoday @BandiniMd @SanRaffaeleMI @MyUniSR
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    May 29, 2025
    Stay tuned on Monday June 2 Hall C 10.15-11.15AM | How to become a successful author @JCO_ASCO @ASCO #ASCO25 #CareerDevelopment #PublicationLounge cdn.bfldr.com/KOIHB2Q3/as/7c…
    579K
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Aug 7, 2025
    Exploratory biomarker analyses of adjuvant #nivolumab in urothelial carcinoma from #CheckMate274 trial are out in @NatureMedicine @MattGalsky | 1. Pre-existing immune infiltration and T-cell infiltration is prognostic and predictive of adj Nivo benefit 2. Composite model
    11K
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Feb 23, 2022
    The PARP inhibitors story and companion bmks in advanced #bladdercancer warrants additional chapters. Great efforts and studies presented at #GU22, several questions remain open to debate @SanRaffaeleMI @SanRaffaeleMI @urotoday @GTumors @MassimoDiMaio75 @DrRosenbergMSK S. Crabb
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Nov 9, 2019
    Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies europeanurology.com/article/S0302-…
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Feb 8, 2024
    @NCCN #bladdercancer Guidelines 2024 now include pembrolizumab as a therapeutic option for pts with BCG-unresponsive Ta/T1 papillary tumors without Tis. Based on the results of Keynote-057 Cohort-B trial @CMercinelli @vale_tateo @Anto_cigliola @urotoday @UroDocAsh @PGrivasMDPhD
    5.1K
  • user avatar
    Andrea Necchi
    @AndreaNecchi
    Feb 11, 2021
    THE review on #penilecancer is out doi.org/10.1038/s41572… @DiseasePrimers @GTumors @SpiessPhilippe @MaartenAlbersen

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up